

**Peripheral and Central Nervous System (PCNS)  
Advisory Committee for Natalizumab (Tysabri) in the  
Treatment of Multiple Sclerosis**

*March 7-8, 2006*

**Table of Contents**

Tab

- 1 Advisory Committee Draft Agenda
- 2 FDA Clinical Review
- 3 FDA Statistical Review
- 4 FDA Office of Drug Safety Risk Minimization Action Plan (RiskMAP) Review
- 5 Questions to Advisory Committee
- 6 New England Journal of Medicine publications of Natalizumab-related PML cases
  - a. Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., Verbeeck J., Geboes K., Robberecht W., Rutgeerts P. Brief Report: Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease. *N Engl J Med* 2005; 353:362-368, July 28, 2005.
  - b. Kleinschmidt-DeMasters B.K., Tyler K.L. Brief Report: Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. *N Engl J Med* 2005; 353:369-374, July 28, 2005.
  - c. Langer-Gould A., Atlas S. W., Green A. J., Bollen A. W., Pelletier D. Brief Report: Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab. *N Engl J Med* 2005; 353:375-381, July 28, 2005.
- 7 Original Approved Package Insert (dated November 2004)